BetterLife Pharma Inc Cash Flow Conversion Efficiency
BetterLife Pharma Inc cash flow conversion efficiency. Based on the latest financial reports, BetterLife Pharma Inc (NPAU) has a cash flow conversion efficiency ratio of 0.030x as of July 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-172.31K ≈ $-201.45K USD) by net assets (€-5.81 Million ≈ $-6.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BetterLife Pharma Inc (2017–2025)
Cash flow conversion efficiency of BetterLife Pharma Inc from 2017 to 2025. This chart illustrates how BetterLife Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NPAU stock price for real-time trading data and today's change.
BetterLife Pharma Inc Cash Flow Conversion Ratio Explained
BetterLife Pharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BetterLife Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BetterLife Pharma Inc ranked by their cash flow conversion efficiency. Also see BetterLife Pharma Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Questor Technology Inc.
V:QST
|
-0.015x |
|
Future Metals NL
AU:FME
|
-0.069x |
|
Elite Education Group International Ltd
NASDAQ:EEIQ
|
-0.327x |
|
Anglo Asian Mining Plc
LSE:AAZ
|
0.159x |
|
Rain Enhancement Technologies Holdco, Inc. Class A Common Stock
NASDAQ:RAIN
|
0.131x |
|
Robogroup
TA:ROBO
|
-0.260x |
|
Twin Vee Powercats Co
NASDAQ:VEEE
|
-0.112x |
|
Manas Enerji Yonetimi Sanayi & Ticaret AS
IS:MANAS
|
-0.018x |
Annual Cash Flow Conversion Efficiency for BetterLife Pharma Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of BetterLife Pharma Inc from 2017 to 2025. Review how financially flexible is BetterLife Pharma Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-01-31 | €-7.36 Million ≈ $-8.61 Million |
€-2.02 Million ≈ $-2.36 Million |
0.275x | -14.52% |
| 2024-01-31 | €-7.70 Million ≈ $-9.00 Million |
€-2.47 Million ≈ $-2.89 Million |
0.321x | +60.97% |
| 2023-01-31 | €-7.53 Million ≈ $-8.81 Million |
€-1.50 Million ≈ $-1.76 Million |
0.200x | -93.09% |
| 2022-01-31 | €-3.88 Million ≈ $-4.54 Million |
€-11.20 Million ≈ $-13.10 Million |
2.887x | +85.82% |
| 2021-01-31 | €-4.61 Million ≈ $-5.39 Million |
€-7.16 Million ≈ $-8.38 Million |
1.553x | +152.37% |
| 2020-01-31 | €2.66 Million ≈ $3.11 Million |
€-7.88 Million ≈ $-9.21 Million |
-2.966x | -121.11% |
| 2019-01-31 | €3.51 Million ≈ $4.10 Million |
€-4.71 Million ≈ $-5.50 Million |
-1.342x | -113.38% |
| 2018-01-31 | €-55.99K ≈ $-65.46K |
€-561.52K ≈ $-656.48K |
10.029x | +5290.49% |
| 2017-01-31 | €-1.93 Million ≈ $-2.26 Million |
€-359.45K ≈ $-420.23K |
0.186x | -- |
About BetterLife Pharma Inc
BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the t… Read more